Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | DRRX |
---|---|---|
09:32 ET | 5048 | 0.9 |
09:34 ET | 500 | 0.9438 |
09:36 ET | 400 | 0.9438 |
09:45 ET | 7668 | 0.92 |
09:48 ET | 500 | 0.920117 |
09:52 ET | 107 | 0.9538 |
09:54 ET | 11540 | 0.9111 |
09:57 ET | 100 | 0.95 |
10:26 ET | 696 | 0.9 |
10:28 ET | 219 | 0.9111 |
10:33 ET | 300 | 0.9001 |
10:44 ET | 100 | 0.9199 |
11:02 ET | 100 | 0.919999 |
11:04 ET | 1000 | 0.903749 |
11:31 ET | 10080 | 0.9 |
11:36 ET | 800 | 0.911501 |
12:07 ET | 800 | 0.9 |
12:32 ET | 2500 | 0.8999 |
12:39 ET | 3106 | 0.89 |
12:45 ET | 1500 | 0.89 |
12:48 ET | 808 | 0.89 |
12:50 ET | 100 | 0.89 |
01:06 ET | 4300 | 0.89 |
01:14 ET | 891 | 0.8899 |
01:28 ET | 2257 | 0.91 |
01:50 ET | 500 | 0.9207 |
02:24 ET | 100 | 0.93 |
02:42 ET | 475 | 0.92 |
03:54 ET | 27419 | 0.92 |
03:56 ET | 100 | 0.92965 |
03:57 ET | 13173 | 0.92965 |
03:59 ET | 51333 | 0.93 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
DURECT Corp | 28.9M | -1.1x | --- |
Bolt Biotherapeutics Inc | 30.2M | -0.5x | --- |
Aspira Women's Health Inc | 33.1M | -1.5x | --- |
VBI Vaccines Inc | 18.1M | -0.1x | --- |
Spruce Biosciences Inc | 30.9M | -0.7x | --- |
Tonix Pharmaceuticals Holding Corp | 18.8M | 0.0x | --- |
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $28.9M |
---|---|
Revenue (TTM) | $8.3M |
Shares Outstanding | 31.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.94 |
EPS | $-0.87 |
Book Value | $0.49 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 3.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -379.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.